Table 1 Study baseline characteristics and quality assessment
First author/Publication year | Study Design/Country | Number of patients | Mean Age(Y) | Male (%) | Outcome Measure | Time of sampling | NLR analysis | HR/OR(95%CI) | Cut off value | Variables adjusted | Quality score |
|---|---|---|---|---|---|---|---|---|---|---|---|
Lou Q/2024 [23] | Retrospective cohort study/America | 785 | 63.4 ± 16.7 | 456(58.1%) | 30-day mortality | Day1 | per 1-unit/SD, <6.0, 6.0–11.3, >11.3 | 1.06 (1.03–1.09) Ref 0.90 (0.66–1.23) 1.54 (1.18–2.02) | 14.15 | Age, sex, race, BMI, DBP, heart rate, oxygen saturation, respiratory rate, hemoglobin, C-reactive protein, hematocrit, hemoglobin, blood urea nitrogen, prothrombin time, International Normalized ratio, alcohol abuse, Glasgow Come Scale, SAPS II, and SOFA | 6 |
Li W/2019 [24] | Retrospective cohort study/China | 224 | 64 (46–77) | 140(62.5%) | 28-day all-cause mortality | Day1 | <9.16, 9.16–16.61, 16.61–26.2, >26.2 | Ref. 1.674 (0.462–6.063), 5.075 (1.554–16.576), 5.815 (1.824–18.533) | 20.34 | Age, sex, body mass index, smoking status, alcohol abusing status, risk factors, comorbidities, baseline vital signs,laboratory data and APACHE II score. | 8 |
Wang Y/2017 [25] | Retrospective cohort study/China | 247 | 62 [48–73] | 162(65.6%) | 28-day all-cause mortality | Day1 | per 1-unit/SD | 1.532(1.095- 2.143) | NA | Age, invasive mechanical ventilation, PaO2/FIO2, surgical history, smoking, APACHE II score, malignant tumor, Liver cirrhosis, non-pulmonary sepsis, HCT (%),neutrophils (109/L, NLR, Platelets, Na, K, BUN, Cr | 6 |
Zhang W/2021 [26] | Retrospective cohort study/America | 1164 | 60.27 ± 17.74 | 479(41.2%) | 30-day mortality | Day1 | per 1-unit/SD, <7.5, 7.5–14.8, ≥14.8 | 1.02(1.01, 1.03), Ref. 1.09 (0.74, 1.60) 1.48 (1.02, 2.16) | NA | Age, gender, ethnicity, smoking, admission type, COPD, hypertension, tumor, diabetes mellitus, renal failure, SID30, pneumonia, sepsis, aspiration, trauma/surgery, othernon-pulmonary, PaO2/FiO2, SAPSII, OASIS, SOFA, corticosteroids therapy, antibiotic therapy, vasopressor therapy, ventilation received, and renal replacement therapy | 6 |
Chen H/2021 [27] | Prospective cohort study/China | 215 | NA | 131(60.9%) | 28-day mortality | Day1 | per 1-unit/SD | 2.803(1.817–4.849) | 13.96 | Age, pathogenic factors, surgical history, invasive and noninvasive sequential mechanical ventilation, RDW, NLR, PAR, and the APACHE II and MLIS scores | 7 |
Yang L/2021 [28] | Retrospective cohort study/China | 268 | NA | 192(71.6%) | 28-day mortality | Day1 | per 1-unit/SD | 0.972 (0.950–0.994) | 29 | PaO2/FiO2, Lactate, MLR, NLR, APACHE II score, SOFA score, Alimentotherapy, Albumin infusion, Transfusion, CRRT, Hospital length of stay | 8 |
Wang Q/2021 [29] | Retrospective cohort study/China | 357 | 58.00 (45.00–69.00) | 184(51.5%) | 30-day mortality | Day1 | per 1-unit/SD | 9.48 (3.39–26.52) | 14.35 | NA | 6 |
Nie S/2022 [30] | Retrospective cohort study/China | 136 | NA | 91(66.9%) | 28-day mortality | Day1 | per 1-unit/SD | 5.22(2.31,18.95) | 14.20 | NA | 7 |